Nanox.AI

Nanox.AI delivers on its promise of turning routine CT scans into opportunistic screening exams. The core strengths are regulatory clearance (7 FDA clearances, 2 CE marks), clinical evidence (12 research publications, ADOPT study showing improved fracture detection), and seamless PACS/RIS integration. The suite covers three high-impact conditions: coronary artery disease, osteoporosis, and fatty liver disease. For health systems, the ROI is tangible: Corewell Health increased coronary calcification detection from 268 to nearly 4,000 patients in one year. Weaknesses include the inability to assess pricing without contacting sales, which frustrates budget planning. There is also no API for custom integrations, and performance depends on specific CT protocols. The platform is not designed for point-of-care or emergency settings. For hospitals already performing many CTs, Nanox.AI adds value with minimal friction. For smaller imaging centers, the pay-per-scan model (likely) may be less attractive without volume. Overall, Nanox.AI is a strong choice for enterprise-level preventive health programs.

Nanox.AI is a clinical decision-support platform that uses deep learning to analyze standard, non-contrast CT scans for early indicators of chronic diseases like cardiovascular disease, osteoporosis, and fatty liver disease. Its suite includes HealthCCSng (coronary artery calcium scoring), HealthOST (vertebral fracture detection and bone density), and HealthFLD (liver fat quantification). These tools integrate with PACS and RIS, flagging incidental findings without additional imaging or contrast. The platform is FDA 510(k) cleared and CE marked, with clinical validation across large populations. It is designed for radiology departments, health systems, and preventive screening programs aiming to shift from reactive to preventive care.